JOURNAL ARTICLE

Recent and anticipated novel drug approvals for 2023 and 2024.

  • Published In: American Journal of Health-System Pharmacy, 2024, v. 81, n. 6. P. 199 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Rim, Matthew H; Karas, Brittany L; Barada, Farah; Levitsky, Andrew M 3 of 3

Abstract

This article provides an overview of novel drug approvals anticipated from the fourth quarter of 2023 through the third quarter of 2024, focusing on agents expected to have significant clinical and financial impact in hospitals and clinics. It highlights 31 drugs from a pipeline of 58 novel agents under FDA review, including treatments for oncology, infectious diseases, rare diseases, pulmonary arterial hypertension, chronic obstructive pulmonary disease, diabetes, and obesity. Notable approvals include cellular and gene therapies for genetic disorders and rare diseases, monoclonal antibodies for autoimmune conditions, and new antimicrobials targeting resistant infections. The article serves as a resource for health-system pharmacists to manage formularies and optimize clinical programs based on emerging therapies.

Additional Information

  • Source:American Journal of Health-System Pharmacy. 2024/03, Vol. 81, Issue 6, p199
  • Document Type:Article
  • Subject Area:Law
  • Publication Date:2024
  • ISSN:1079-2082
  • DOI:10.1093/ajhp/zxad337
  • Accession Number:175938050
  • Copyright Statement:Copyright of American Journal of Health-System Pharmacy is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.